Top Markets
Coin of the day
Chinook Therapeutics, Inc. Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc.

KDNY
Hisse Senetlerindeki Sıralama #7141
Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical... Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical development phase, is dedicated to the identification, progression, and market introduction of precise medical treatments for kidney-related conditions. The company's primary therapeutic candidate, atrasentan, is an endothelin receptor antagonist currently in Phase III clinical trials. This drug aims to treat IgA nephropathy and various other glomerular diseases characterized by proteinuria. Beyond its lead program, Chinook's investigational pipeline includes BION-1301, an anti-APRIL monoclonal antibody, which is presently being evaluated in a Phase I/II study for IgA nephropathy. Another promising candidate is CHK-336, an oral small molecule designed to inhibit LDHA, intended for patients with primary hyperoxaluria. The firm also maintains active research initiatives exploring solutions for other uncommon and severe chronic kidney ailments. Chinook Therapeutics, Inc. is based in Seattle, Washington.
Hisse Fiyatı
$40.39
Son senkronizasyon: 2023-08-18
Piyasa Değeri
$1.70B
Değişim (1 gün)
0.00%
Değişim (1 yıl)
0.00%
Ülke
US
Ticaret Chinook Therapeutics, Inc. (KDNY)

Kategori

Chinook Therapeutics, Inc. (KDNY) için EPS
2026 itibariyle EPS TTM: 0
Chinook Therapeutics, Inc. şirketinin en son finansal raporlarına ve hisse senedi fiyatına göre, şirketin mevcut EPS'si (TTM) 0'dir. 2026 yılı sonunda, şirketin EPS'si 0 idi; bu, 2026 yılındaki EPS olan 0 ile önceki yıla eşit.
Chinook Therapeutics, Inc. için 2026 - 2026 arasındaki EPS geçmişi
Her yıl sonunda EPS
Yıl EPS Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakipler için EPS
Şirket EPS EPS Farkı Ülke
$17.32 -
US
$27.74 -
NL
$-5.29 -
AU
$-7.98 -
US
- -
CH